Wang Kai, Chen Songhua, Wang Xiaomeng, Zhong Jieming, Wang Xinting, Huai Pengcheng, Wu Limin, Wang Lixia, Jiang Shiwen, Li Jun, Peng Ying, Yao Hongyan, Ma Wei
1 Department of Epidemiology and Health Statistics, Shandong University School of Public Health , Jinan, China .
Microb Drug Resist. 2014 Aug;20(4):294-300. doi: 10.1089/mdr.2013.0145. Epub 2013 Dec 13.
Multidrug-resistant tuberculosis (MDR-TB) has emerged as a serious global public health problem. In China, the risk factors for MDR-TB have not been systematically evaluated.
To identify risk factors associated with MDR-TB among previously treated patients in China.
A case-control study was carried out. Cases were selected from previously treated MDR-TB patients who were resistant to both isoniazid and rifampin, and controls were selected from previously treated TB patients who were sensitive to isoniazid and rifampin (non-MDR-TB). Information was collected from the registration database and a structured questionnaire.
A total of 61 cases and 50 controls were recruited. A multivariate analysis showed that the family annual per-capita income ≤7,000 Yuan (odds ratio [OR]=3.238; 95% confidence interval [CI]: 1.270-8.252), no history of fixed dose combinations (FDCs) in anti-TB treatment (OR=4.027; 95% CI: 1.457-11.129), and adverse reactions in the course of TB treatment (OR=3.568; 95% CI: 1.402-9.085) were independent predictors of MDR-TB. Moreover, among the TB patients who had adverse reactions, quitting the treatment was shown as a risk factor for MDR-TB (p=0.009).
In the control of MDR-TB among previously treated patients, lower socioeconomic groups, the expanding use of FDCs, and improving adherence to treatment by implementing Directly Observed Therapy Short Course-Plus (DOTS-Plus), strictly should become a priority that requires strong commitment and collaboration among health organizations.
耐多药结核病(MDR-TB)已成为一个严重的全球公共卫生问题。在中国,MDR-TB的危险因素尚未得到系统评估。
确定中国既往治疗患者中与MDR-TB相关的危险因素。
开展一项病例对照研究。病例选自既往治疗的对异烟肼和利福平均耐药的MDR-TB患者,对照选自既往治疗的对异烟肼和利福平敏感的结核病患者(非MDR-TB)。从登记数据库和一份结构化问卷中收集信息。
共招募了61例病例和50例对照。多因素分析显示,家庭年人均收入≤7000元(比值比[OR]=3.238;95%置信区间[CI]:1.270-8.252)、抗结核治疗中无固定剂量复合制剂(FDCs)使用史(OR=4.027;95%CI:1.457-11.129)以及结核病治疗过程中的不良反应(OR=3.568;95%CI:1.402-9.085)是MDR-TB的独立预测因素。此外,在有不良反应的结核病患者中,中断治疗是MDR-TB的一个危险因素(p=0.009)。
在既往治疗患者的MDR-TB控制中,社会经济地位较低的群体、扩大FDCs的使用以及通过实施强化直接观察治疗(DOTS-Plus)提高治疗依从性,应严格成为卫生组织之间需要坚定承诺和协作的优先事项。